Vanguard Capital Management LLC has filed an amended Schedule 13G, revealing its ownership stake in EyePoint Inc. As of October 30, 2026, Vanguard holds 4.99% of EyePoint's common stock, amounting to 4,306,688 shares. This update is significant as it highlights Vanguard's ongoing investment strategy and its influence in the laboratory analytical instruments sector.

EyePoint Inc, which specializes in laboratory analytical instruments, has undergone several name changes in its history, previously known as EyePoint Pharmaceuticals, Inc. and pSivida Corp. The company is incorporated in Delaware and has its principal executive office located in Watertown, Massachusetts.

The filing states, "This Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates..." Vanguard's holdings include securities managed by its various affiliates, emphasizing its extensive reach in managing assets.

This update may affect EyePoint's strategic decisions as it navigates the competitive landscape of the laboratory analytical instruments industry. Vanguard's sizable stake could lead to increased scrutiny on the company's performance and future initiatives.

The filing does not specify what actions Vanguard may take next regarding its stake in EyePoint Inc.

Details of Ownership

Vanguard Capital Management LLC's filing indicates that it possesses sole voting power over 637,314 shares of EyePoint's common stock, while holding full dispositive power over the entire 4,306,688 shares. This structure highlights Vanguard's significant influence over the management of these shares.

Furthermore, the filing clarifies that Vanguard's ownership is classified as 4.99% of EyePoint's total common stock, confirming that it does not exceed the 5% threshold that would require different reporting obligations.

Affiliates Involved

The amended Schedule 13G also reveals that Vanguard Capital Management LLC's holdings include securities managed by its affiliates, such as Vanguard Asset Management Limited and Vanguard Investments Australia Ltd. This breadth of management underscores Vanguard's extensive capabilities in asset management.

Legal and Compliance Notes

In compliance with SEC regulations, Vanguard certifies that the securities were acquired and are held in the ordinary course of business, without the intent to influence control of EyePoint Inc. This statement is crucial for maintaining regulatory compliance and reflects Vanguard's investment strategy focused on asset management rather than control.

"This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power..."

Overall, this filing not only updates Vanguard's stake in EyePoint but also provides insight into its operational structure and compliance with regulatory requirements.